Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 02/10 03:59:59 pm
144.81 USD   +1.15%
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/08 UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

04/24/2012 | 04:40pm US/Eastern

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

React to this article
Latest news on AMGEN, INC.
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/08 UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's
02/07 AMGEN : Gibraltar Road Climb to Conclude Third Stage of Amgen Tour of California
02/07DJDrug Industry Launches Ad Campaign Aimed at Lawmakers
02/05 AMGEN : To Present At The Leerink Partners 5th Annual Global Healthcare Conferen..
02/05 AMGEN : Positive topline results from GAUSS-3 trial of Repatha
02/05 AMGEN : Phase 3 study of Blincyto in ALL meets primary endpoint
02/04 AMGEN : Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overal..
02/04 AMGEN : Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repath..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials